PPARGC1A and type 2 diabetes mellitus: SR18292, a PGC-1α inhibitor, leads to dysfunction in OXPHOS metabolism, energy exhaustion, and oxidative damage, thus impairing the proliferation and survival of multiple myeloma cells.609 Metformin, a first-line drug treatment for T2DM, also increases H2O2-induced cancer cell death.